Madrigal’s MGL-3196 Achieves Primary Endpoint in Patients with Biopsy-proven Non-alcoholic Steatohepatitis (NASH) in Phase 2 Clinical TrialDecember 6, 2017
Madrigal Pharmaceuticals Reports 2017 Third Quarter Financial ResultsNovember 9, 2017
Madrigal Pharmaceuticals Presents Preclinical Results Supporting the Therapeutic Potential of its Lead β-Selective Thyroid Hormone Receptor Agonist, MGL-3196, at AASLD Liver MeetingOctober 23, 2017
Press Release History
Website Developed by Alan Leff Associates, Inc.